Endocrine therapy in premenopausal women with breast cancer

A critical appraisal of current evidence

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Nearly 60% of all breast cancer premenopausal women are diagnosed with a hormone receptor positive tumor and, therefore, are candidates for adjuvant hormonal therapy. Treatment with tamoxifen for at least 5 years has been for a long time the standard of care, as it is associated with overall positive clinical outcomes. However, in the last decade, a number of studies on adjuvant endocrine therapy in premenopausal women with hormone receptor positive breast cancer have been published, adding a bulk of evidence to existing knowledge in this field. A critical appraisal of their results appears necessary in order to put the recently collected data into the current framework of treatment, and to discuss the several issues that remain open. Here, we review the most recent evidence on the following: the optimal duration of tamoxifen treatment, results of the studies comparing tamoxifen alone to tamoxifen plus ovarian function suppression (OFS), results of the studies comparing tamoxifen plus OFS to aromatase inhibitors plus OFS.

Original languageEnglish
Pages (from-to)211-218
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume16
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Tamoxifen
Breast Neoplasms
Hormones
Therapeutics
Aromatase Inhibitors
Standard of Care
Neoplasms

Keywords

  • Breast cancer
  • ovarian function suppression
  • premenopausal
  • tamoxifen

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

@article{5200b34b050c48879bcc8f6e68c65c0c,
title = "Endocrine therapy in premenopausal women with breast cancer: A critical appraisal of current evidence",
abstract = "Nearly 60{\%} of all breast cancer premenopausal women are diagnosed with a hormone receptor positive tumor and, therefore, are candidates for adjuvant hormonal therapy. Treatment with tamoxifen for at least 5 years has been for a long time the standard of care, as it is associated with overall positive clinical outcomes. However, in the last decade, a number of studies on adjuvant endocrine therapy in premenopausal women with hormone receptor positive breast cancer have been published, adding a bulk of evidence to existing knowledge in this field. A critical appraisal of their results appears necessary in order to put the recently collected data into the current framework of treatment, and to discuss the several issues that remain open. Here, we review the most recent evidence on the following: the optimal duration of tamoxifen treatment, results of the studies comparing tamoxifen alone to tamoxifen plus ovarian function suppression (OFS), results of the studies comparing tamoxifen plus OFS to aromatase inhibitors plus OFS.",
keywords = "Breast cancer, ovarian function suppression, premenopausal, tamoxifen",
author = "Filippo Montemurro and {Del Mastro}, Lucia and {De Laurentiis}, Michele and Fabio Puglisi",
year = "2016",
month = "2",
day = "1",
doi = "10.1586/14737140.2016.1128327",
language = "English",
volume = "16",
pages = "211--218",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Endocrine therapy in premenopausal women with breast cancer

T2 - A critical appraisal of current evidence

AU - Montemurro, Filippo

AU - Del Mastro, Lucia

AU - De Laurentiis, Michele

AU - Puglisi, Fabio

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Nearly 60% of all breast cancer premenopausal women are diagnosed with a hormone receptor positive tumor and, therefore, are candidates for adjuvant hormonal therapy. Treatment with tamoxifen for at least 5 years has been for a long time the standard of care, as it is associated with overall positive clinical outcomes. However, in the last decade, a number of studies on adjuvant endocrine therapy in premenopausal women with hormone receptor positive breast cancer have been published, adding a bulk of evidence to existing knowledge in this field. A critical appraisal of their results appears necessary in order to put the recently collected data into the current framework of treatment, and to discuss the several issues that remain open. Here, we review the most recent evidence on the following: the optimal duration of tamoxifen treatment, results of the studies comparing tamoxifen alone to tamoxifen plus ovarian function suppression (OFS), results of the studies comparing tamoxifen plus OFS to aromatase inhibitors plus OFS.

AB - Nearly 60% of all breast cancer premenopausal women are diagnosed with a hormone receptor positive tumor and, therefore, are candidates for adjuvant hormonal therapy. Treatment with tamoxifen for at least 5 years has been for a long time the standard of care, as it is associated with overall positive clinical outcomes. However, in the last decade, a number of studies on adjuvant endocrine therapy in premenopausal women with hormone receptor positive breast cancer have been published, adding a bulk of evidence to existing knowledge in this field. A critical appraisal of their results appears necessary in order to put the recently collected data into the current framework of treatment, and to discuss the several issues that remain open. Here, we review the most recent evidence on the following: the optimal duration of tamoxifen treatment, results of the studies comparing tamoxifen alone to tamoxifen plus ovarian function suppression (OFS), results of the studies comparing tamoxifen plus OFS to aromatase inhibitors plus OFS.

KW - Breast cancer

KW - ovarian function suppression

KW - premenopausal

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84957430023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957430023&partnerID=8YFLogxK

U2 - 10.1586/14737140.2016.1128327

DO - 10.1586/14737140.2016.1128327

M3 - Article

VL - 16

SP - 211

EP - 218

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 2

ER -